Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical is making progress in its pre-conditional privatization of Shanghai Henlius Biotech by merger, as it continues to liaise with Chinese authorities to fulfill necessary pre-conditions. The company has delayed the dispatch of the Composite Document, now expected by May 2025 or upon pre-condition fulfillment. This move is part of Fosun’s strategic efforts to streamline its operations within the pharmaceutical sector.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
